<unk>  (PEP/MPA) is a combination of<unk><unk>  (PEP), an estrogen, and<unk>  acetate (MPA), a progestin, which was studied in the 1960s as a long-lasting combined injectable contraceptive for women but was never marketed. It was administered by intramuscular injection once every 3 months and contained 40 mg PEP and 150 mg MPA. The combination was studied in a sample of 99 premenopausal women and was found to be effective in preventing pregnancy, but caused menstrual irregularities similar to those of MPA alone as a progestogen-only injectable contraceptive. PEP was included in the formulation to prevent estrogen deficiency and reduce menstrual abnormalities caused by MPA during long-term contraceptive therapy.
Polyestradiol phosphate/medroxyprogesterone acetate
Mestranol/hydroxyprogesterone acetate
Ethinylestradiol/megestrol acetate
Ethinylestradiol/desogestrel
Norelgestromin/ethinylestradiol
Ethinylestradiol/levonorgestrel
Nomegestrol acetate/estradiol
Segesterone acetate/ethinylestradiol